Drugs / ABA-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06566261 | Sep 2024 → Feb 2026 overdue | multiple sclerosis | Abata Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABA-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06566261 ↗ |
| Modality | Cell therapy | “TCR engineered, autologous regulatory T cell (Treg) therapy” NCT06566261 ↗ |